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Abstract
Background: Preclinical models of pediatric cancers are essential for testing new chemotherapeutic combinations for
clinical trials. The most widely used genetic model for preclinical testing of neuroblastoma is the TH-MYCN mouse. This
neuroblastoma-prone mouse recapitulates many of the features of human neuroblastoma. Limitations of this model include
the low frequency of bone marrow metastasis, the lack of information on whether the gene expression patterns in this
system parallels human neuroblastomas, the relatively slow rate of tumor formation and variability in tumor penetrance on
different genetic backgrounds. As an alternative, preclinical studies are frequently performed using human cell lines
xenografted into immunocompromised mice, either as flank implant or orthtotopically. Drawbacks of this system include
the use of cell lines that have been in culture for years, the inappropriate microenvironment of the flank or difficult, time
consuming surgery for orthotopic transplants and the absence of an intact immune system.
Principal Findings: Here we characterize and optimize both systems to increase their utility for preclinical studies. We show
that TH-MYCN mice develop tumors in the paraspinal ganglia, but not in the adrenal, with cellular and gene expression
patterns similar to human NB. In addition, we present a new ultrasound guided, minimally invasive orthotopic xenograft
method. This injection technique is rapid, provides accurate targeting of the injected cells and leads to efficient
engraftment. We also demonstrate that tumors can be detected, monitored and quantified prior to visualization using
ultrasound, MRI and bioluminescence. Finally we develop and test a ‘‘standard of care’’ chemotherapy regimen. This
protocol, which is based on current treatments for neuroblastoma, provides a baseline for comparison of new therapeutic
agents.
Significance: The studies suggest that use of both the TH-NMYC model of neuroblastoma and the orthotopic xenograft
model provide the optimal combination for testing new chemotherapies for this devastating childhood cancer.
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Introduction
Neuroblastoma (NB) is responsible for 15% of all childhood
cancer deaths and is the most common cancer diagnosed during
the first year of life [1]. NB arises in the developing sympathetic
nervous system, in precursor cells thought to be derived from the
neural crest tissues [2]. The tumors appear in the adrenal medulla
or along the paraspinal ganglia in the abdomen, chest, pelvis or
neck [3,4].
A new International Neuroblastoma Risk Group (INRG)
classification system of the disease divides the patients to 16 risk
groups from the lowest risk group with localized tumor that can be
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the highest risk group that presents with metastasis to bone
marrow and bone and currently has only 40 to 50% survival rate
[5,6]. A unique patient group is the 4S which usually occurs in
infants less then one year of age and has a favorable prognosis with
a greater than 90% survival rate. Although the tumors in the 4S
group develop very early, they undergo spontaneous regression
[7]. Full regression is also seen in some of the stage 1 tumors with
localized disease [8].
Amplification of N-MYC (.10 copies per cell) occurs in about
30% of NB human patients and is strongly correlated with
advanced disease stage and poor outcome [9–11]. Several studies
show that MYC proteins can act as master transcriptional factors
to activate or repress a wide variety of genes [12,13]. In addition
the MYC family proteins including MYCN can influence
expression of genes through deregulation of microRNAs [14–
17]. Importantly, high expression of N-myc is sufficient to induce
neuroblastoma tumor formation in transgenic mice [18].
The TH-MYCN transgenic mouse model, in which N-myc
expression is driven by a 4.5 Kb promoter of the rat tyrosine
hydroxylase gene (TH) which is expressed specifically in neural
crest lineage cells, is now a widely used murine model of NB [18].
Tumor penetrance in this transgenic NB model is strain dependent
[18]. NB tumors arise in the TH-MYCN transgenic model at high
frequency on the 129SvJ background, with ,33% of the
hemizygous transgenic mice and 100% of the homozygous mice
developing tumors. The reason for the high tumor frequency on
the 129SvJ background compared to other murine genetic
backgrounds, such as the BL6 strain which has only 5% tumor
occurrence, is still not clear but is attributed to strain-specific
modifiers not identified yet.
Overexpression of N-MYC in the mouse peripheral neural crest
of the TH-MYCN mice gives rise to NB tumors that recapitulate
many of the histological and pathological aspects of human NB
[18–20]. In addition, genome-wide array CGH analysis of the
murine tumors identified distinct genomic aberrations that share
some similarity with those in human tumors [21]. Cell lines
derived from the mouse tumors display many of the molecular
characteristics of human NB [22] although the tumors rarely
exhibit loss of the mouse gene region that is syntenic with
chromosome 1p36 or metastasize to distant organs such as bone
marrow [21,23].
Several recent studies have utilized the TH-MYCN transgenic
model to understand the in vivo functions of additional genes
involved in NB pathogenesis such as p53 and Mdm2 [24,25].
Importantly, this murine model has been very useful in assessing
the clinical efficacy of potential new drugs for NB like the
angiogenesis inhibitor HPMA copolymer-TNP-470 conjugate
(caplostatin) [24] and the ornithine decaroboxylase inhibitor a-
difluoromethylornithine [26].
In this study, we provide additional characterization of the TH-
MYCN mouse model using multiple diagnostic imaging method-
ologies and gene profiling. In addition, we present a new approach
for generating orthotopic xenografts of neuroblastoma using
ultrasound guided injections of neuroblastoma cells into the
adrenal or para-adrenal space, where 40% of human NB tumors
arise [3]. To demonstrate the utility of this new orthotopic
xenograft method for neuroblastoma and provide a clinically
relevant benchmark for future preclinical studies, we tested a
chemotherapeutic regimen that is similar to the current standard
of care for induction chemotherapy for neuroblastoma in the
xenograft model. These data set the stage for future generation of
orthotopic xenografts of primary human neuroblastoma and for
testing new agents for this devastating childhood cancer.
Results
Characterization of the cellular features of TH-MYCN
neuroblastoma
To obtain NB tumors from the TH- MYCN model, hemizygous
TH-MYCN transgenic mice were bred onto the 129SvJ
background. Tumors arose on this background at a frequency of
,33%. Tumors could first be detected visually in the abdomen of
the transgenic mice at 9–13 weeks of age. Earlier tumors could be
routinely identified by imaging (MRI and ultrasound) at week
6(see below). The TH-MYCN mouse tumors appeared to arise in
the ganglion cells, in line with the sympathetic ganglion chain
(Figure 1A.). We characterized these tumors histologically by
Hematoxylin and Eosin (H&E) staining (Figure 1 and Figure S1),
by electron microscopy (Figure S2) and by immunohistochemistry
(IHC) staining with neuronal markers (Figure 1). Ki67 staining was
also employed to evaluate proliferation (Figure 1M). H&E and
IHC staining revealed substantial heterogeneity within the
primary tumors and the presence of microscopic (,1m m
3)
metastatic lesions in the lungs (100% of the animals), ovaries
(44%), abdominal lymph nodes (32%) and bone marrow (5%) of
3–5 months old mice. The majority of the H&E stained tumor
cells were variably sized, blue cells, with generally prominent
nucleoli and distinct nuclear membranes that grew in solid sheets,
cords and molded pavement patterns (Figure 1B and Figure S1A–
D). However, there were also regions of much larger cells that had
a more ganglion-like appearance in the primary mouse tumors
(Figure 1C and Figure S1E,F).
Analysis of the developing primary TH-MYCN tumors (mouse
ages 9–13 weeks) by immunohistochemistry revealed that the
mouse tumors stained homogenously for the neuronal markers:
protein gene-product 9.5 (PGP9.5), chromogranin A, synaptho-
pysin and neurofilament protein (NFP) (Figure 1D–G). However,
there was heterogeneity in the staining patterns with other
neuronal markers including neuron specific enolase (NSE),
microtubule-associated protein 2 (MAP-2) and tyrosine hydroxy-
lase (TH), a marker of more differentiated cells. These proteins
were strongly expressed only in areas of ganglion-like cells within
the tumors (Figure 1H–L). The regions of the tumors that stained
positive for the markers NSE, MAP-2 and TH were also the only
areas that were not undergoing proliferation as judged by the
absence of Ki67 staining (Figure 1M). In contrast, the majority of
the cells in the tumors stained positive for Ki67, indicating
potential proliferation, but failed to express the markers NSE, TH
and MAP-2 (Figure 1H–L). Numerous mitotic figures were also
present in these areas while the areas surrounded by the more
differentiated ganglion-like cells exhibited an absence of mitotic
figures and often surrounded by necrotic and apoptotic cells
(Figure 1H, J). Electron microscopy of the TH-MYCN tumors and
human tumors revealed features consistent with neuronal
differentiation including dense core neurosecretory vesicles,
synaptic junctions and processes typical of neuronal cells (Figure
S2). There were also areas of lipids dispersed throughout the
tumors.
Overall, these data are consistent with previous characterization
of the TH-MYCN neuroblastomas and they suggest that the
mouse neuroblastomas most closely resembled a class of aggressive
human neuroblastoma tumors classified as large cell neuroblasto-
ma [27–29]. This subgroup of tumors is composed of cells that are
markedly larger than other NB subgroups and have unique,
sharply outlined nuclear membranes and 1–4 prominent nucleoli.
Tumor with this morphology are found within the undifferentiated
and poorly differentiated classes of NB and are seen most often in
cases with MYCN amplified tumors.
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To extend these findings, we isolated RNA from 18 samples
of hemizygous abdominal TH-MYCN tumors and performed
Affymetrix gene expression array analysis. These tumors which
were representative of full grown progressive tumors, weighing
1.5 gr+/20.75 gr, were harvested from 12 females and 6 males
8–13 week old mice. All eighteen samples clustered tightly on
principle component analysis (PCA) analysis (data not shown).
Human NB data were obtained from three previously published
neuroblastoma studies using the Affymetrix U133 v2 chip and
combined to give a total of 125 gene expression arrays (Figure
S3) for comparison. The data was then examined by PCA and
collated with meta data describing each tumor (Figure S3). The
125 arrays were adjusted by batch correction method included
in Partek Genomics Suite 6.4. Data from Affymetrix human
U133 v2 arrays and mouse Affymetrix 430 v2 arrays were
processed using the RMA algorithm. This data was then used
to examine data quality by PCA for each species separately.
The corrections described above removed much of the
variability across the human array data from the different
studies (Figure S3).
Next were removed genes that did not have documented
orthologs, between humans and mice, using the Affymetrix’s
ortholog mapping document derived from National Center for
Biotechnology Information’s (NCBI) Homologene database. The
probesets corresponding to 15646 unique human and mouse
unigene pairs were retained. Each subset of the original data from
mouse and human data sets was then converted to quartiles to
further normalize the data and to concentrate on large differences
between the species. Once quartiled, the data within each unigene
id was averaged and the resulting means were compared across
species.
The batch corrected set of human neuroblastomas and the
mouse N-MYC tumors unigene pairs were then assigned grades
(A+ - D) based on the performance of probesets that were designed
to measure the same transcript in the same array. The purpose of
this grading was to distinguish consistent measurements from
variable ones. The quartile range across all observations within a
given unigene and species represents technical and biological
variability but does not influence grade. However, the range of
probeset signals within a unigene does influence the grade. If the
range for all probesets for a particular unigene within a species was
less than or equal to 1 quartile it was given an A+ grade. A total of
424 A+ unigene pairs (2.7% of the total unigenes, 424/15646
unigenes) from all stages and MYCN status exhibited expression
differences of one or more quartiles between human and mouse
and were termed differential (Table S1). Gene ontology, using
DAVID’s GO analysis [30] showed statistically significant
enrichment for genes in the immune response among the 424
differential genes (Table S1). 125 of these genes showed differences
in expression of 2 quartiles or more, up or down, between the two
species across all disease stages and MYCN status (Table S2).
Figure 1. Histology and immunohistochemistry of mouse TH-MYCN tumors. Tumors that arose along the paraverterbral ganglia
predominately exhibited (A), a solid cord (B) and molding/pavement morphologies (C) although areas of cells with a ganglion-like appearance were
dispersed throughout the tumors (see arrow). The tumors stained homogenously for the neuronal markers- PGP9.5 (D), chromogranin A (E),
synaptophsin (F) and neurofilament protein (G). However, only the ganglion-like cells within the tumor stained strongly positive for the neuronal
markers - neuron specific enolase (H, I), microtubule associated protein 2 (J, K), Tyrosine Hydroxylase (L). These ganglion-like cells were negative for
the proliferation marker Ki67 (M).
doi:10.1371/journal.pone.0019133.g001
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to their expression in normal adrenal tissue (A+ only) of the
appropriate species and subtracted these species differences there
were 18 unigenes that were differentially expressed between
human tumors and mouse tumors (Table S3). These 18 unigenes
are presented in Table S3. Among them we find breast cancer 2
early onset gene 2 (BRCA2) which was expressed at significantly
higher levels in the mouse tumors.
When we compared the TH-MYCN mouse tumor microarray
expression data to the human NB patient data (A+ quality data
only as described above) classified by disease stage and restricted to
MYCN amplified patients, we found high similarity between
stages 3 and 4 of human disease and the mouse model (see
Table 1). Interestingly, there were no genes that had a statistically
different level of expression in the stage 4 N-MYC amplified
human tumors versus mouse tumors and only 53 genes were
differentially expressed between mouse and human stage 3
MYCN–amplified samples. Taken together the histological
analysis and the molecular analysis suggest that the TH-MYCN
mouse model most closely resembles stages 3 and 4 N-MYC
amplified human neuroblastoma.
Ultrasound guided injection of neuroblastoma cells in
mice
While the TH-MYCN tumors had molecular and cellular
features of Stage 4 NMYC amplified human neuroblastomas, one
major difference was the relatively low rate of distant metastasis in
these mice. It is possible that orthotopic xenografts of primary
human neuroblastomas or cell lines would more efficiently
metastasize than the tumor cells in the TH-MYCN mouse model.
Most previous studies focused on xenografts of neuroblastoma
have involved flank engraftment or engraftment to the kidney
capsule or more rarely engaftment into the adrenal using surgical
procedures. However, the microenvironment of the flank is very
different from that of the normal site of neuroblastoma initiation
and the surgical procedure is relatively slow and can be associated
with morbidity. In order to establish a minimally invasive, high
throughput method for efficient introduction of neuroblastoma cell
lines and primary human tumor cells into the mouse we developed
an ultrasound guided technique to inject cells directly into the
adrenal or the para-adrenal space. These two areas were chosen
because a high percentage of human tumors (40%) are found in
these areas [4]. The advantage of this technique is that it is
relatively rapid (10–12 mice can be injected per hour), it leads to
efficient engraftment of neuroblastoma cell lines (.80%) and there
is no morbidity associated with the technique (see Materials and
Methods).
Five human NB cell lines were chosen to demonstrate the
feasibility and utility of this approach - NB5, NB7, NB1691
[23,32,31], SKNAS (ATCC CRL-2137) and SKNSH (ATCC
HTB-11). These cell lines were selected because they differ in N-
myc amplification, caspase-8 expression, p53 mutation status and
1p36 LOH [23,32]. The cells were labeled with luciferase by stable
transfection with a retrovirus expressing the luciferase gene.
Luciferase expression was tested and quantified in the Xenogen
Imager before injecting the cells into the mice. Single suspension
cells were mixed with matrigel in a total volume of 10 ml and
implanted into the para-adrenal area, between the adrenal and the
kidney or into the adrenal medulla itself. Injections were done with
the aid of an ultrasound-guided catheter and needle (See Materials
and Methods). Tumor formation and growth was monitored for
up to 24 weeks.
Orthotopic ultrasound guided xenografts faithfully recapitulat-
ed many of the histological hallmarks of neuroblastoma.
Xenografts showed some heterogeneity in terms of cell size and
immunohistochemical staining patterns (Figure 2), and the
presence of cells with a more differentiated somewhat ganglion-
like appearance in tumors from some but not all cell lines. Similar
to the mouse tumors, all tumors of the xenografts tumors stained
positive for the neuroendocrine marker PGP 9.5 (Figure 2).
Mitotic figures were consistently seen (Figure 2) and proliferation,
indicated by Ki67, was notably greater in areas around blood
vessels and at the peripheral margins of the tumor (Figure 2).
Regions of xenografts were also immunoreactive for synaptophy-
sin, neuron specific enolase (NSE) and tyrosine hydroxylase (TH),
however; these markers were not as ubiquitously expressed as
PGP 9.5 (Figure 2).
Electron microscopy also demonstrated that the xenograft
tumors resembled the human N-MYC amplified tumors as well as
the murine TH-MYCN tumors. The human xenograft tumors
contained areas enriched in dense core synaptic vesicles and
synapses and junction typical of neuronal cells (Figure S2). There
were also areas of lipids dispersed throughout the tumors.
Tumor growth was monitored by sequential Xenogen imaging.
Growth curves generated from this data are shown in Figure 3.
Paradrenal xenografts established from cell line NB1691 showed
the most aggressive growth rates reaching a tumor volume of
600 mm
3 after 31.8+/28.8 days (n=5). NB5 paradrenal
xenografts grew slightly slower, reaching a volume of 600 mm
3
after 52.2+/29.8 days (n=6) when transplanted into the
retroperitoneal space near the adrenal or 36+/23.5 days (n=3)
when injected directly into the adrenal gland. Only 20% (3/15) of
paradrenal SKNSH xenografts reached a volume of 600 mm
3 and
this took on average 103.3+/223.4 days (n=3) (Figure S4). The
remainder of SKNSH xenografts either failed to engraft (based on
permanent loss of the Xenogen signal that was present
immediately after injection) or regressed (initially signal was
maintained or increased slightly during first few weeks and then
gradually disappeared). Similarly, NB7 xenografts demonstrated
inconsistent engraftment and growth with only 2/19 mouse
tumors reaching a volume of 600 mm
3, one after 43 days and the
other after 142 days (Figure S4). The remaining NB7 xenografts
either failed to engraft or remained as steady disease (maintained
bioluminescent signal without evidence of growth) throughout the
study. Thus, overall, xenografts from NB1691, NB5, and SKNAS
provide consistent engraftment and growth rates whereas,
xenografts from NB7 and SKNSH are less reliable.
Diagnostic imaging of neuroblastomas in mice
While the orthotopic xenograft studies had demonstrated the
utility of Xenogen imaging for monitoring tumor growth, our
preliminary studies indicated that the volume measurement
remained linear when the tumors were relatively small but
Table 1. Differential gene expression between MYCN
amplified human neuroblastoma by disease stages and
mouse TH-MYCN tumors.
Human Stage
(N-MYC amplified)
Number of differences
from mouse TH-MYCN tumors
1 135
2 231
35 3
40
doi:10.1371/journal.pone.0019133.t001
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tested the ability of ultrasound to accurately assess tumor volume
in both model systems. For these studies, we imaged a cohort of 26
mice TH-MYCN hemizygous weekly or bi-weekly after initial
detection of the tumors by ultrasound and assessed 13 mice with
NB5 orthotopic xenografts. TH-MYCN mice were typically
followed from week 5 through week 12 of age while the xenograft
mice were followed beginning on day 2 after injection and then
monitored weekly for 6–25 weeks. TH-MYCN tumors could be
clearly detected by week 6–9 (Figure 4) while xenograft tumors
were visible between weeks 4–6 (Figure 5). Ultrasound imaging
proved to be an efficient and rapid method for screening large
numbers of mice to identify initial tumors, determine their original
location and for following the tumor growth and volume.
Typically, 8–10 mice could be viewed in an hour time.
MRI on the other hand, provided superior detail and 3D
volume measurements especially with large tumors, and allowed a
more detailed diagnosis of the tumor origin and composition
especially on T2 weighted imaging. This came, however, at the
cost of about 25 min of table time per mouse.
The TH-MYCN tumors (21/26, 81%), first appeared very near
or surrounding the aorta in the paravertebral ganglia of the mice,
while the remaining 19% of the tumors (5/21) initially appeared
closer to the adrenal or kidney by both MRI and ultrasound
(Figure 6). All of the xenograft tumors appeared either in the para-
adrenal region or within the adrenal depending on the site of
injection. Examples of bioluminescence, ultrasound and MRI
imaging of a developing xenograft tumor are shown in Figure 5.
Importantly, both TH-MYCN and xenograft tumor volumes
showed good agreement between the imaging methodologies
(Figures 4 and 5).
Spontaneous tumor regression in TH-MYCN mice
Interestingly, we noticed that 10% of the TH-MYCN tumors (5
out of 50 tumors total) exhibited a clear arrest in the growth
between weeks 8–10 which lasted approximately 2 weeks and was
Figure 2. Histology and immunohistochemical analysis of orthotopic neuroblastoma xenografts. NB5 xenografts transplanted into the
para-adrenal region (A–D) or into the adrenal gland (E–H) stained with hematoxylin and eosin (A, B), the proliferation marker Ki67 (C,G) or PGP9.5
(D,H). NB1691 (I–L) and SKNAS xenografts (M-0) transplanted to the paradrenal region stained with hematoxylin and eosin (I, J, M N), Ki67 (K, O)o r
with the neuroendocrine label PGP 9.5 (L). The scale bars in the left column represents 100 mm and the scale bars in the right 3 columns represents
25 mm. Arrows indicate mitotic figures and blood vessels are labeled.
doi:10.1371/journal.pone.0019133.g002
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and MRI imaging (Figure 7). Hematoxylin and Eosin staining of
the regressed tumors revealed that the cellular morphology of
these tumors was similar to the TH-MYCN tumors that did not
regress (Figure 8A). Infiltration of B and T cells was clearly
observed near the peripheral edges of the tumors by staining with
antibodies B220 and CD3 (Figure 8B,C). The regressed tumors
also had low staining for F4-80, a marker for macrophages
(Figure 8D). Only one of the regressing tumors (#6865) exhibited
a significant increase in the percentage of cells that were
undergoing apoptosis as judged by the presence of activated
caspase-3 (Figure 8G,H compared to 8F). Tumor regression was
also observed in some of the NB7 and SKNSH xenografts as
described above and in Figure S4. Tumors typically regressed
before they reached a volume of 100 mm
3 in both models.
Induction Chemotherapy in Neuroblastoma Orthotopic
Xenografts
The new ultrasound guided neuroblastoma xenograft approach
combined with validation of diagnostic imaging to study tumor
growth and response in vivo provides us with the opportunity to
test new chemotherapeutic agents. To test the feasibility of
preclinical testing in our orthotopic neuroblastoma xenograft
model and establish a baseline response for current standard of
Figure 4. TH-MYCN mouse tumor imaging by MRI and ultrasound. The left column shows tumor progression at four distinct time points
(top: first, button: last) as depicted by T2 weighted MRI. The tumor was manually segmented (red outline) on multi-slice coronal images and the
volume averaged over all slices at each time point. The purple line traces the course of the aorta. Neuroblastomas are typically hypointense on T1-
weighted images (VIBE data not shown) and hyperintense on T2-weighted images and can be seen on these images, especially in the later stages.
The tumors appear to arise ventral to the aorta and demonstrate heterogeneous patterns, possibly from calcifications and hemorrhagic areas.
Ultrasound data, also showing anatomical location of tumor (red) relative to aorta (purple), are presented as single slices (horizontal plane) and
isosurface models generated from 3D data sets. Both imaging methods confirmed rapid growth of these representative tumors (and tight correlation
across modalities) over the 30 day study period as described graphically to the right.
doi:10.1371/journal.pone.0019133.g004
Figure 3. Growth of Orthotopic Neuroblastoma Xenografts. Bioluminescence (left column) and ultrasound volume (center) are plotted
against time after injection (days post injection, dpi) for NB5 para-adrenal (A–C), NB5 intra-adrenal xenografts (D–F) and for NB1691 (G–I) and SKNAS
(J–L) para-adrenal xenografts. A correlation analysis between the bioluminescence (y-axis) and ultrasound volume (x-axis is presented for the various
xenografts in the right column. The correlation co-efficient is provided in the lower right hand of panels C, F, I and L.
doi:10.1371/journal.pone.0019133.g003
Preclinical Models for Neuroblastoma
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Luc was generated by infection of the NB5 cells with luciferase
expressing retrovirus as described in Materials and Methods) into
the left para-adrenal space of nude mice. 2–3 weeks after injection,
we monitored tumor engraftment and enrolled 43 mice on study
that had localized bioluminescent signal (Figure 9A). The majority
of mice (36/43) had signals of $10
6 photons/sec/cm
2 (Figure 9B).
The animals received the same drugs that are routinely
administered for induction chemotherapy to treat neuroblastoma
patients. The first course was cyclophosphamide, doxorubicin and
etoposide (CAE) and the second course was etoposide and cisplatin
(CE) (see Materials and Methods for detailed description of dosing
and toxicity) (Figure 9C). Alternating CAE/CE treatments were
repeated for a total of 6 courses over 18 weeks. Before and after
each course, the tumor burden was monitored by bioluminescence
and ultrasound as described above. Overall, 13/43 (30%) of the
mice treated with induction chemotherapy completed 6 courses of
therapy while all of the untreated mice had progressive disease and
were euthanized by 50 days after being enrolled on study
(Figure 9D). Among those 13 animals that completed therapy, 9
were complete response (CR) as indicated by the absence of
bioluminescence, ultrasound signal (Figure 9G,H), MRI signal
(Figure 8 I,J) and lack of visible tumor at necropsy (Figure 9E,F).
The remaining 4 animals were classified as stable disease and
showed extensive necrosis in histopathological analysis
(Figure 9K,L).
To determine if there was any correlation between tumor size
at diagnosis and outcome, we plotted the initial tumor burden
(bioluminescence) versus the stage when their tumor progressed
and they became moribund (Figure 9M). During the first 3
courses (9 weeks) of therapy, there was a clear relationship
between initial tumor burden and progression (shaded region in
Figure 9M). However, after the 3
rd course, there was no
correlation between initial tumor burden and response to this
standard of care chemotherapy regimen. Moreover, those
animals that showed a complete response or stable disease after
6 courses of therapy had an initial tumor burden of less than
3610
7 cells. Therefore, for future studies, we recommend
enrolling animals with an initial tumor burden for the NB5-Luc
cell line between 1610
4 and 3610
7 cells. To determine if 6
courses of therapy was essential for these studies to identify those
animals that are likely to respond and those that are likely to
progress, we plotted the tumor burden (bioluminescence) of all
animals just before each course (Figure 9N). These data show a
trend toward increased tumor burden over the first 4 courses but
by the 5
th course, those animals with stable disease or complete
response can be clearly identified. Taken together, these data
establish the feasibility of performing preclinical testing of novel
combinations of chemotherapy and provide a benchmark for the
widely used standard of care induction chemotherapy for
neuroblastoma.
Discussion
The studies in this report reveal similarities and differences
between the two mouse tumor model systems. At the cellular
level the two models were highly similar in terms of appearance,
immunohistochemical staining patterns and the presence of
cellular junctions and synaptic dense core vesicles. Tumors from
both models also contained a high percentage of proliferating
cells characterized by both Ki67 staining and a large number of
mitotic cells and exhibited regions with substantial numbers of
necrotic and apoptotic cells. The similarities between the mouse
and human tumors are also highlighted by the gene expression
microarray studies which found a 68.1% Pearson correlation in
quartiled and grade adjusted gene expression. However, there
are also several differences including: the presence of large non-
dividing ganglion-like cells in all the mouse tumors and larger,
somewhat ganglion-like cells in only some of the human
xenografts (xenograft SKNAS, for example, did not contain
ganglion-like cells). In addition, the majority of the mouse
tumors fail to macrometastasize beyond the local area. Eighteen
genes were also differentially expressed (greater than one quartile
difference) in the human and mouse tumors. These differences
may contribute to their tumorigenicity and/or metastatic
abilities. For example the mouse tumors expressed higher levels
of BRCA2, a known tumor suppressor gene in breast and
ovarian cancer and involved in maintenance of genome stability,
specifically the homologous recombination pathway for double-
strand DNA repair [33,34]. We do not yet know if any of these
18 genes account for the differences in disease progression
between the human and mouse neuroblastomas but our
ultrasound guided engraftment procedure is suited for testing
these hypotheses.
Our ultrasound studies showed that 81% of initial tumors in the
TH-MYCN mice are found surrounding or in the vicinity of the
aorta in the paravertebral ganglia. The percentage of tumors in
humans originating from the paraspinal ganglia is ,60% [1,4].
We speculate that this site in the mouse provides factors from the
blood system and from the adjacent adrenal that can enhance
tumor growth and progression. Surprisingly, none of the mouse
NB tumors originated in the adrenal medulla itself as confirmed by
ultrasonography, histology and electron microscopy. These results
are in agreement with recent works observing initial tumor
formation in the TH-MYCN mouse in early postnatal sympathetic
ganglia and not in the adrenal [20,35]. However, in a few cases we
observed that the mouse tumors invaded the adrenal at later stages
of tumor progression. This is in contrast to the human disease
where approximately 40% of the patient tumors originate in the
adrenal medulla [1,4].
Recording the in vivo regression of a small group of TH-MYCN
tumors by ultrasound and MRI opens the possibility of using this
model to study this process and suggests these tumors may exhibit
similarities to human stage 4S tumor which also spontaneously
regress. Understanding the regression process in vivo could help
identify the biological pathways that will facilitate tumor growth
arrest and drive the tumor to complete regression.
The standard of care protocol described in this paper will be
useful for testing new drug compounds, alone or in combination
with the standard CAE/CE treatment, for their efficacy in treating
neuroblastoma. Our study suggests that the most accurate data
will be obtained from combination of both mouse models in
Figure 5. Xenograft neuroblastoma tumors were imaged by ultrasound and MRI. Orthotopic xenografts were produced by ultrasound
guided needle injection of human NB cells to the para-adrenal or adrenal medulla in the mouse (A–C). Tumors were imaged by ultrasound, MRI and
Xenogen imaging (D–F), tumor volumes determined and plotted (G, H). Ultrasound data (C,D) showing anatomical location of tumor (red) relative to
the kidney (green) are presented as single slices (horizontal plane) and/or isosurface models generated from 3D data sets. MRI data are presented as
single slices (frontal plane), again highlighting tumor relative to kidney. Bioluminescence images are presented with tumor highlighted
colorimetrically (photons/second/cm
2/steridian). Combination of the three imaging modalities clearly demonstrates efficient xenograft establishment
and rapid growth from the para-adrenal space with appreciable correlation across the methods.
doi:10.1371/journal.pone.0019133.g005
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PLoS ONE | www.plosone.org 9 April 2011 | Volume 6 | Issue 4 | e19133Figure 6. Location of TH-MYCN tumors as determined by ultrasound imaging. Ultrasound data showing the anatomical location of
representative tumors (red) relative to aorta (purple) and right kidney (green). Data are presented as single slices (horizontal plane) and isosurface
models generated from 3-D data sets which were also used to discern tumor volumes (mm
3). Eighty-one percent of the TH-MYCN tumors (21/26) first
appeared in the paravertebral ganglia adjacent to or surrounding the aorta of the mice, while the remaining 19% of the tumors (5/21) initially
appeared closer to the adrenal or kidney.
doi:10.1371/journal.pone.0019133.g006
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system allows testing of the drugs in an immune proficient model
while the orthotopic xenograft system uses human cells grown in
the proper microenvironment. The ultrasound guided injection
technique can also be used to generate a new bank of
neuroblastoma patient xenografts by injecting cells directly from
the patient tumors into mice and subsequently passaging the
tumors without ever growing the cells in culture. This xenograft
Figure 7. Monitoring of regressing TH-MYCN tumors by imaging. Regressing TH-MYCN tumors were imaged by ultrasound and MRI between
weeks 8–10 and tumor volumes were determined. Ultrasound data (left panels) showing anatomical location of tumor (red), aorta (purple), right
kidney (green) and left kidney (blue). Data are presented as single slices (horizontal plane) and/or isosurface models generated from 3D data sets
(middle panels). MRI data are presented as T2 weighted single slices (frontal plane), again highlighting tumor relative to kidney (right panels).
doi:10.1371/journal.pone.0019133.g007
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to treatments that are more tailored to individual patients.
Materials and Methods
Animals
TH-MYCN hemizygote mouse were purchased from NCI
mouse repository (strain # 01XD2) on genetic background
129X1/SvJ and kept on this genetic mouse background. CD-1
nude immunodefecient mice were purchased from Charles River
(strain code 087, heterozygous).
This study was carried out in strict accordance with the
recommendations in the Guide to Care and Use of Laboratory
Animals of the National Institute of Health. The protocol was
approved by the Institutional Animal Care and Use Committee at
St. Jude Children’s Research Hospital (IACUC protocols 420 and
393). All efforts were made to minimize suffering. All mice were
bred and housed in accordance with approved IACUC protocols.
Animals were housed on a 12-12 light cycle (light on 6am off 6pm)
and provided food and water ad libitum.
Generation of Bioluminescent Cell Lines
NB cell lines NB5, NB7, NB1691 [23,31,32], SKNAS (ATCC
CRL-2137), and SKNSH (ATCC HTB-11) were infected with a
MSCV-luciferase-IRES-zeocin retrovirus. Zeocin selection was
initiated 48 hours after infection as described previously [36]
(Institution Biohazard Committee approval 02-152). After selec-
tion the cell lines were screened to verify luciferase activity. Cells
were maintained in RPMI-1640 medium with 10% fetal calf
serum.
Immunohistochemistry and electron microscopy of the
tumors
Paraffin-embedded formalin-fixed tumors were immunostained
for histochemical analysis with the following antibodies: B220
(CD45R/B220) (B.D. Biosciences, CA, USA, cat. 553084)
(dilution 1:10,000), Caspase-3 (BioCare Medical, CA, USA, cat.
CP229C) (dilution 1:100), CD3 (Santa Cruz, CA, USA, cat. sc-
1127) dilution 1:350), Chromogranin (Immunostar, WI, USA, cat.
20085) dilution 1:5,000), F4/80 (Caltag, CA, USA, cat. MS48000)
dilution 1:1,000), Ki67 (ThermoShandon, CA, USA, cat. RM-
9106) (dilution 1:200), MAP-2 (Millipore, CA, USA, cat. AB5622)
(dilution1:250), NFP (DAKO, CA,USA, cat. MO762) (dilution
1:40), NSE (DAKO, CA, USA, cat. MO873) (dilution 1:50),
Perforin (Abcam, MA, USA, cat. ab16074) (dilution1:4,000),
PGP9.5 (Morphosystems, NC, USA, cat. 7863-0504) (dilu-
tion1:10,000), Synaptophysin, (ThermoShandon, CA, USA, cat.
RM-9111) (dilution1:100) and TH (Vector, CA, USA, cat. VP-
T489) (dilution 1:40).
TH-MYCN, xenograft and human patient tumors were fixed
for electron microscopy in 4% glutaraldehyde in 0.1 Msodium
cacodylate buffer pH 7.4 with 5% sucrose and post fixed in 0.2%
osmium tetroxide in 0.1 M sodium cacodylate buffer with 0.3%
potassium ferrocyanide for 2 hours. After rinsing in same buffer
the tissue was dehydrated through a series of graded ethanol to
propylene oxide, infiltrated and embedded in epoxy resin and
polymerized at 70uC overnight. Semithin sections (0.5 micron)
were stained with toluidine blue for light microscope examination.
Ultrathin sections (70 nm) were cut and stained with Reynolds
lead citrate. Examinations were made with a FEI Tecnai F20
Figure 8. Morphology and immunohistochemistry of regressing TH-MYCN tumors. (A), Regressing tumor 620 stained with H&E, B-cell
marker, B220 (B), T-Cell marker, CD3 (C), macrophage cells marker F4-80 (D), a CD8 T-cells and natural killer cells marker Perforin-1 (E) and cleaved
caspase-3 (F). Regressing tumor 6865 stained with cleaved caspase-3 (G, H).
doi:10.1371/journal.pone.0019133.g008
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PLoS ONE | www.plosone.org 12 April 2011 | Volume 6 | Issue 4 | e19133Figure 9. Induction chemotherapy in neuroblastoma. (A) Representative Xenogen image of an NB5-Luc orthotopic xenograft and uninjected
control at enrollment. Scale is photons/sec/cm
2.( B) Histogram of proportion of the 43 animals shown by tumor burden as measured by Xenogen. (C)
Schedule of the etoposide, doxorubicin, cyclophosphamide (CAE) and the etoposide, cisplatin (CE) courses of chemotherapy. (D) Survival curve for 43
mice treated with alternating courses of CAE and CE for 18 weeks (6 courses) and 10 untreated control animals. The tumor burden was monitored by
Xenogen and ultrasound. 30% of the mice survived therapy while all of the untreated mice reached moribund status within 50 days (E,F) Photograph
of kidney (k) and para-adrenal space of a representative animal with progressive disease (PD) and complete response (CR). (G,H) Representative 3D
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The use of human patient samples was approved by the
institutional review board of St. Jude Children’s’ Research
Hospital (XPD09-113) and all subjects provided written consent.
The study was conducted in accordance with the Declaration of
Helsinki.
Ultrasound-Guided Para- or Intra-adrenal Xenografts
All ultrasound procedures were performed using the VEVO-
770, fitted with a RMV-706 probe. Cells were suspended in
Matrigel (BD Worldwide, Cat#354234) at a concentration of
2610
4 cells per microliter and placed on ice. Anesthetized
recipient CD1 nude mice (isoflurane 1.5% in O2 delivered at
2 liters/min) were placed laterally on the imaging bed such that
the left flank faced upward. In order to provide a channel for
delivery of the implant, a 22 gauge catheter (BD Worldwide, Cat#
381423) was gently inserted through the skin and back muscle into
the para-adrenal region and the hub was removed. A chilled
Hamilton syringe fitted with a 27 gauge needle (1.25 inch) and
loaded with 10 ml of the cell suspension was guided steretoactically
through the catheter and positioned between the kidney and
adrenal gland as visualized using ultrasound. The cells were
injected into the region and the needle was left in place for 0.5–
1 min in order to permit the matrigel component to set. The
needle was then slowly removed, followed by gentle removal of the
catheter. The same procedures were used for intra-adrenal
injections although in these studies the needle was used to pierce
the adrenal capsule and cells were deposited into the medulla of
the adrenal gland.
Bioluminescent Imaging and Quantification
For Xenogen imaging mice were given intraperitoneal injec-
tions of Firefly D-Luciferin (Caliper Life Sciences 3 mg/mouse).
Bioluminescent images were taken five minutes later using the
IVISH 200 imaging system. The Living Image 3.2 software
(Caliper Life Sciences) was used to generate a standard region of
interest (ROI) encompassing the largest tumor at maximal
bioluminescence signal. The identical ROI was used to determine
the average radiance (photons/s/cm
2/sr) for all xenografts from
all time points. Biolumicescence and ultrasound volume per
individual animal were plotted on a double Y axis using
Kaleidagraph Software using the most appropriate scale for each
cell line.
Ultrasound imaging of the TH-MYCN mice and
Xenografts
All ultrasound studies were performed using the VisualSonics
VEVO-770 High Frequency Ultrasound system (VisualSonics,
Toronto, Canada). Briefly, animals were anesthetized (isoflurane
1.5% in O2 delivered at 2 liters/min) and hair covering the area to
be imaged removed by application of hair removal cream (Nair).
For scanning, animals were placed prone on the imaging stage,
ultrasound transmission gel (Parker Labs inc., USA) liberally
applied and the relevant transducer (RMV-706 at 40 MHz)
lowered stereotactically to the surface of the animal. Tumor
(normally characterized by irregular regions of hypoechoicity) was
identified relative to normal tissue landmarks and volumes were
determined by acquisition of high resolution (50–100 mm in-plane)
images with a step size of 100 mm providing a close to isotropic
data set. Tumor perimeters were then traced at 0.5 mm intervals
and the VisualSonics software used to render and calculate
calibrated volumes.
Once luminescence was above 10
6 photons/s/cm
2/sr in the
xenografted animals, imaging was perfomed weekly with the
Visualsonic VIVO-770 ultrasound system fitted with the RMV-
706 probe at a frequency of 40 MHz. The field of view was set
15615 mm. Weekly three-dimensional scans of the tumors were
reconstructed using the Visualsonics software. Tumor margins
were traced and volume measurements were determined by the
Visualsonics software. Bioluminescence and ultrasound volume
per individual animal were plotted on a double Y axis using
Kaleidagraph Software. Each cell line is represented with the best
scale for that cell line.
MRI imaging of the TH-MYCN mice and the Xenografts
Magnetic Resonance Imaging (MRI) was performed using a 7-
Tesla Bruker Clinscan animal MRI scanner (Bruker BioSpin MRI
GmbH, Germany) equipped with a Bruker BGA12S gradient
(660 mT/m with 4570 T/m/s slew rate). Animals were anesthe-
tized using isoflurane (1.5–3% in O2) for the duration of data
acquisition. Briefly, animals were restrained on an MR safe bed
(Bruker BioSpin MRI GmbH, model number T10211) in a prone
head-in-first position. A 4 channel phased-array rat brain coil
(Bruker) was used for signal reception. The coil was centered over
the kidneys of the mice.
For Contrast Enhanced MR studies (CE-MRI), contrast agent
(0.1 mmol/kg, Magnevist, Berlex, Montville, NJ), which corre-
sponds to 50 mL of diluted contrast agent for a 25 g mouse, was
injected through a tail-vein catheter [37,38] and immediately
flushed with 25 mL saline.
A stack of 25 coronal, T2 weighted, Turbo Spin Echo (TSE)
[39] images (0.5 mm thickness) was acquired with no gap between
the slices. The field of view (FOV) was 35635 mm
2 with a matrix
size of 2566256. The echo time (TE) was 60 ms and the repetition
time (TR) was 2610 ms. Receiver bandwidth (BW) was 235 Hz/
pixel. 4 averages were used. For CE-MRI, VIBE [40] was used to
rapidly acquire a T1 weighted 3D volume before and after
injection. Orientation, matrix and FOV were identical to the T2
weighted images. 3D slab thickness was 14 mm with 56 slice
encoding steps; the resulting voxel size was 0.1460.1460.25 mm
3.
Other sequence parameters were: TR=10 ms, TE=2 ms, flip
angel=15u. A partial Fourier factor of 6/8 was used in phase
encoding, and slice selection direction. Each scan took 1.5 minutes
and was repeated 12 times without pause to provide a time-course.
Injection of contrast agent was performed immediately after the
4
th VIBE sequence. All images were read and processed on a
Siemens console using Syngo MR B15 software (Siemens AG,
Erlangen, Germany).
ultrasound and tracing with volume measurements for a representative PD and CR showing volumes for adrenal (blue), kidney (green), aorta (purple)
and tumor (red). (I, J) Examples of MRI of an animal with PD showing displacement of the kidney from the tumor growth (I) and a CR animal after
completion of treatment showing normal kidney adrenal positions (arrow in J) where the tumor was previously located. (K,L) H&E staining of tumors
from mice with CR and PD. Arrow indicates region of necrosis. (M) Plot of tumor burden at diagnosis as measured by bioluminescence (xenogen and
the course of chemotherapy when the animal became moribund. The gray shaded region with dashed line indicates the minimum burden at each
course where progression could be detected. The group of CR and SD that completed 6 courses of therapy are highlighted in green. (N) Histogram of
tumor burden just before each course of chemotherapy. Bars represent the mean and standard deviation of all surviving animals at each time point.
Scale bars: K, L, =50 mm.
doi:10.1371/journal.pone.0019133.g009
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RNA was extracted from TH-MYCN mouse tumors using
Trizol reagent (Invitrogen) . RNA quality was confirmed by
analysis on the Agilient 2100 Bioanalyzer. Total RNA (100 ng)
was processed in the Hartwell Center microarray core according
to the Affymetrix eukaryote two-cycle target assay (http://media.
affymetrix.com/support/downloads/manuals/expression_analy-
sis_manual.pdf). Biotin-labeled cRNA (10 ug) was hybridized
overnight at 45uC to the Mouse Genome 430 2.0 GeneChip
array which interrogates more than 39,000 transcripts. After
staining and washing, arrays were scanned and expression values
summarized using the MAS5 algorithm as implemented in the
GCOS v1.4 software (Affymetrix, Santa Clara, CA). Signals were
normalized for each array by scaling to a 2% trimmed mean of
500. Probe set annotations were obtained from the Affymetrix
website (http://www.affymetrix.com/analysis/index.affx) [41]. All
data is MIAME compliant and the raw data has been deposited in
a MIAME compliant database (GEO Gene Expression Omnibus
at NCBI). See Figure S3 for more details on the microarray
analysis and methods. GEO number (GSE27516).
Standardized treatment of the xenograft tumors
CD1-nude mice were injected with 10 mL of NB5-luciferase
cells (2610
4/uL) into the para-adrenal space. These mice were
then screened weekly by Xenogen and the bioluminescence was
measured. The target bioluminescence signal for enrollment was
10
5–10
8 photons/sec/cm
2 (median 6.51610
6, mean 5.65610
7).
Once this signal was reached the animals were enrolled and
started chemotherapy the following Monday.
The chemotherapeutic drug combinations and schedule used in
this study was designed to mimic the most common treatments of
neuroblastoma in human patients. These drug combinations have not
been published previously in mice. Therefore, when possible, relevant
drug dosages were determined using pharmacokinetic studies
(specifically, area under the curve analysis) conducted previously on
mice and humans to determine appropriate doses for the study. Once
enrolled, the mice received 6 courses of alternating chemotherapy
with each course lasting 21 days (18 weeks total). All drugs were
administered systemically by intraperitoneal injection. The drugs
given during courses 1, 3, and 5 included cisplatin 2 mg/kg (daily on
days 1–5) and etoposide 5 mg/kg (daily on days 2–4). The drugs given
during courses 2, 4, and 6 included cyclophosphamide 125 mg/kg
(daily on days 1–2), doxorubicin 3.5 mg/kg (day 1) and etoposide
1.3 mg/kg (day 1) then 6 mg/kg (daily on days 2–4). Additionally,
each mouse received 1 ml of 0.9% normal saline subcutaneously
(daily on days 1–5) to help maintain hydration. The animals did not
receive chemotherapy during days 6–21 during each course.
The health of the animals was monitored daily throughout the
therapy. Standard complete blood counts with differential (CBC-
Ds) were obtained prior to the initiation of each course of
chemotherapy. For CBC-D collection, approximately 30 mLo f
blood was collected from the facial vein and diluted with standard
amounts of EDTA. Samples were processed immediately using the
FORCYTETM Hematology Analyzer (Oxford Scientific, Oxford,
CT). Moribund status was defined as tumor burden greater than
20% body mass, at which point the animal was euthanized.
Supporting Information
Figure S1 Variable morphology was seen in the TH-
MYCN tumors. Most areas consist of solid cords (A, B), with area
with a molding/pavement appearance (C,D). Ganglion-like pockets
of cells were spread throughout the tumors (E,F). 406magnification.
(TIF)
Figure S2 Electron microscopy of a representative TH-
MYCN tumor, orthotopic human NB tumors and a Stage
4 MYCN-amplified patient tumor. A representative TH-
MYCN tumor (upper left), a human stage 4 patient tumor
(upper middle) and xenograft tumors derived from neuroblas-
toma cell lines SKNSH (upper right), NB1691 (lower left),
NB5 (lower middle) and SKNAS (lower right). The general
appearance of the tumors is shown in (A) dense core vesicle,
junctions, lipids and processes (B–D).
(TIF)
Figure S3 PCA analysis of human microarray data.
Human NB data were obtained from three GEO neuroblastoma
studies. Each source is represented by a different dot color. The
left panel shows the principal components (PC) analysis before
correction for NB data source. Axes are: x=PC1 explains 13.70%
of the variability of the data, y=PC2 explains 9.34% of the
variability of the data and z=PC3 explains 6.86% of the
variability of the data. The right panel shows the components
(PC) analysis after correction for NB source. Axes are: x axis PC1
explains 13.10% of the variability of the data, y axis=PC2
explains 7.27% of the variability of the data and z axis=PC3
explains 5.76% of the variability of the data.
(PDF)
Figure S4 Growth of additional orthotopic neuroblasto-
ma xenografts. Bioluminescence (left column) and ultrasound
(middle column) plotted against time after injection (days post
injection, dpi) for SKNSH (A) and NB7 (B). A correlation analysis
between the bioluminescence (y-axis) and ultrasound volume (x-
axis is presented for the various xenografts in the right column.
The correlation co-efficient is provided in the (upper corner of
right column).
(TIF)
Table S1 Data on the 424 unigenes that differ between
mouse and human by at least one quartile.
(XLS)
Table S2 Data on the 125 unigenes of interest NB differ
between mouse and human by at least two quartiles.
(XLS)
Table S3 Data on the 18 unigenes that exhibit at least
two quartile differences but do not exhibit species
differences in the adrenal.
(XLS)
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